Abstract
This article reviews the preclinical pharmacology of neuroleptics, with focus on the newer generation compounds: clozapine, risperidone, olanzapine, sertindole, and quetiapine. All of these newer compounds are considered to be atypical neuroleptics, based on certain criteria, which are reviewed. Several hypotheses about the molecular mechanisms that explain atypicality are considered. Finally, the in vitro receptor binding data presented for these and some older compounds are related to the therapeutic and adverse effects of these drugs.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antipsychotic Agents / adverse effects
-
Antipsychotic Agents / classification
-
Antipsychotic Agents / pharmacology*
-
Dopamine D2 Receptor Antagonists
-
Drug Interactions
-
Female
-
Humans
-
In Vitro Techniques
-
Male
-
Receptors, Adrenergic, alpha / drug effects
-
Receptors, Adrenergic, alpha / metabolism
-
Receptors, Dopamine D2 / drug effects
-
Receptors, Histamine / drug effects
-
Receptors, Histamine / metabolism
-
Receptors, Muscarinic / drug effects
-
Receptors, Muscarinic / metabolism
-
Receptors, Serotonin / drug effects
-
Receptors, Serotonin / metabolism
-
Structure-Activity Relationship
Substances
-
Antipsychotic Agents
-
Dopamine D2 Receptor Antagonists
-
Receptors, Adrenergic, alpha
-
Receptors, Dopamine D2
-
Receptors, Histamine
-
Receptors, Muscarinic
-
Receptors, Serotonin